Man Group’s Terns Pharmaceuticals TERN Stock Holding History

Man Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15M	Buy	+284,931	New	+$11.7M	0.03%	641
2025 Q2	–	Sell	-38,472	Closed	-$106K	–	2383
2025 Q1	$106K	Buy	+38,472	New	+$157K	﹤0.01%	2106
2023 Q1	–	Sell	-13,763	Closed	-$132K	–	1849
2022 Q4	$140K	Buy	+13,763	New	+$91.6K	﹤0.01%	1844

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Man Group's TERN Position: Q1 2026 in Review

Man Group opened a new position in Terns Pharmaceuticals (TERN) in Q1 2026: 284,931 shares worth $15M. The stake represents 0.03% of the portfolio and ranks #641 among its holdings. This is a return to the name: Man Group previously reported a position in TERN as recently as Q1 2025.

Man Group first reported a position in TERN in Q4 2022 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Man Group held 284,931 shares of Terns Pharmaceuticals worth $15M as of Q1 2026.
Terns Pharmaceuticals was a new Man Group position in Q1 2026.
Terns Pharmaceuticals made up 0.03% of Man Group's portfolio in Q1 2026, its #641 holding.
Man Group first reported a position in Terns Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.